Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.70 |
| ▸ | VDR | P11473 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.70 |
| ▸ | CDC25A | P30304 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | PGR | P06401 | 2/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.70 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.70 |
| ▸ | DRD3 | P35462 | 1/20 | 0.70 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL232217 | 0.90 | MAPT (0.74) | MAPTVDRMEN1KMT2AADORA3 | |
| SCHEMBL4960177 | 0.90 | MAPT (0.74) | MAPTVDRMEN1KMT2AADORA3 | |
| SCHEMBL8003899 | 0.90 | MAPT (0.74) | MAPTVDRMEN1KMT2AADORA3 | |
| SCHEMBL10034122 | 0.90 | MAPT (0.74) | MAPTVDRMEN1KMT2AADORA3 | |
| SCHEMBL9330205 | 0.88 | MAPT (0.71) | MAPTVDRMEN1KMT2AADORA3 | |
| SCHEMBL3824860 | 0.88 | MAPT (0.70) | MAPTVDRMEN1KMT2AADORA3 | |
| SCHEMBL3698818 | 0.87 | MAPT (0.69) | MAPTVDRMEN1KMT2AADORA3 | |
| SCHEMBL6842113 | 0.87 | MAPT (0.69) | MAPTVDRMEN1KMT2AADORA3 | |
| SCHEMBL10034118 | 0.87 | MAPT (0.69) | MAPTVDRMEN1KMT2AADORA3 | |
| SCHEMBL260762 | 0.87 | MAPT (0.69) | MAPTVDRMEN1KMT2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093675-A1 | NOVEL METHOD | BIOXELL S.P.A. (IT) | 2010-04-15 | — | — | US | disclosed |
| US-20100069339-A1 | NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY | BIOXELL S.P.A. (IT) | 2010-03-18 | — | — | US | disclosed |
| US-20090298800-A1 | 1,25-DIHYDROXY, 20-CYCLOPROPYL,26-27-DEUTEROALKYL VITAMIN D3 COMPOUNDS AND METHODS OF USE THEREOF | BIOXELL S.P.A. (IT) | 2009-12-03 | — | — | US | disclosed |
| US-20080318911-A1 | 20-Cyclopropyl, 26,27-Alkyl/Haloalkyl Vitamin D3 Compounds and Methods of Use Thereof | BIOXELL S.P.A. (IT) | 2008-12-25 | — | — | US | disclosed |
| US-20080064668-A1 | 1,3-Diacylated, 26,27-Alkyl/Haloakyl Vitamin D3 Compounds and Methods of Use Thereof | BIOXELL S.P.A. (IT) | 2008-03-13 | — | — | US | disclosed |
| US-20080039434-A1 | Treatment of Interstitial Cystitis with Vitamin D Compounds | BIOXELL S. P.A. (IT) | 2008-02-14 | — | — | US | disclosed |
| US-20070054887-A1 | Methods for treating bladder dysfunction | BIOXELL S.P.A (IT) | 2007-03-08 | — | — | US | disclosed |
| US-20060258630-A1 | More selective and specific immunotherapy with improved side effect reduction; carbon 20 is substituted with methyl or cyclopropyl, carbon 16 is a single or double bond, and carbon 23 is a single, double, or triple bond; vitamin deficiency | BIOXELL S.P.A. (IT) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258630-A1 | More selective and specific immunotherapy with improved side effect reduction; carbon 20 is substituted with methyl or cyclopropyl, carbon 16 is a single or double bond, and carbon 23 is a single, double, or triple bond; vitamin deficiency | CYP24A1, CYP2R1, VDR | MAPT 2652/4885VDR 3/4885MEN1 2384/4885 |
| US-20100069339-A1 | NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY | CYP27B1, CYP2R1, SHBG | MAPT 4547/4885VDR 5/4885MEN1 3826/4885 |
| US-20080064668-A1 | 1,3-Diacylated, 26,27-Alkyl/Haloakyl Vitamin D3 Compounds and Methods of Use Thereof | CYP24A1, VDR, CYP2R1 | MAPT 4687/4885VDR 2/4885MEN1 1616/4885 |
| US-20080039434-A1 | Treatment of Interstitial Cystitis with Vitamin D Compounds | VDR, CYP24A1, CYP2R1 | MAPT 3603/4885VDR 1/4885MEN1 3963/4885 |
| US-20070054887-A1 | Methods for treating bladder dysfunction | CYP27B1, CYP24A1, VDR | MAPT 3931/4885VDR 3/4885MEN1 3462/4885 |
| US-20080318911-A1 | 20-Cyclopropyl, 26,27-Alkyl/Haloalkyl Vitamin D3 Compounds and Methods of Use Thereof | CYP2R1, CYP24A1, VDR | MAPT 4735/4885VDR 3/4885MEN1 4100/4885 |
| US-20090298800-A1 | 1,25-DIHYDROXY, 20-CYCLOPROPYL,26-27-DEUTEROALKYL VITAMIN D3 COMPOUNDS AND METHODS OF USE THEREOF | CYP24A1, CYP2R1, VDR | MAPT 4416/4885VDR 3/4885MEN1 2526/4885 |
| US-20100093675-A1 | NOVEL METHOD | GC, VDR, CYP24A1 | MAPT 4570/4885VDR 2/4885MEN1 3743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.